2025 Arnold Caplan Award RECLAIM: A Translational Platform for Cartilage Repair and Musculoskeletal Tissue Regeneration Using Allogeneic MSCs
Related Experiment Video
Updated: Jan 15, 2026

Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots
Published on: May 21, 2013
1From the Mayo Clinic Rochester, MN, and the Department of Orthopedics, Utrecht University, the Netherlands.
Abstract:
Cartilage defects remain a prevalent and challenging clinical problem, especially in young, active individuals. Existing treatments such as microfracture or autologous chondrocyte implantation either lack durability or require multiple surgeries and extensive cell culture. To address these limitations, we developed RECLAIM-a one-stage, two-cell-type procedure combining allogeneic mesenchymal stromal cells and autologous chondrons. RECLAIM harnesses the trophic and immunomodulatory properties of MSCs to stimulate autologous chondron-driven tissue repair, minimizing invasiveness while optimizing biologic regeneration. This article reviews the preclinical discovery, clinical translation, trial results, and platform potential of RECLAIM, which was recognized with the 2025 Arnold I. Caplan Award for Distinguished Research in OrthoBiologics. Our work builds on Professor Caplan's pioneering conceptualization of MSCs as "medicinal signaling cells" and establishes a model for academic, investigator-driven translation of regenerative science into clinical practice.
Related Concept Videos
Mesenchymal Stem Cells
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

